Companies / RNV

RENERVE LIMITED

ASX:RNVHealth Care Equipment & Services

172.3M shares on issueASX (delayed) · as of 28 July 2026$0.080price · delayed$13.3Mmarket cap · indicative

Dilution gradeprovisional — limited history

Runway under 2 quarters; share count grew 27% in 24 months; 3 cash raises in 24 months

Cash runway0.5 quarters of funding

Share-count growth (24m)27.2%

Raise cadence (24m)3 cash raises

Options & rights overhang24.4% of shares

In-the-money supply0.0% of shares

Pending proposed issuesopen proposed issue (Appendix 3B)

RENERVE LIMITED's ordinary share count grew 27.2% between March 2025 and March 2026, to 139M shares. The company raised capital three times in that period for total disclosed proceeds of A$7.8M, most recently a convertible note funding facility / placement of convertible notes raising A$1.4M in July 2026. Options and rights on issue could convert into 42M new shares, equal to 24.4% of the current share count, of which 0% are in the money; the nearest expiry is November 2027. At the March 2026 quarter RENERVE reported A$969K in available cash, about 0.5 quarters of funding at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026

24.4%

Max option dilution

0.0%

ITM option dilution

Raises · last 12 months

0.5 qtrs

Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue

Weekly counts from ASX records. Dots mark cash capital raises. Latest count 172.3M per ASX (delayed) (28 July 2026).

Cash runway

0.5 qtrs

Less than two quarters of funding at the recent spend rate — near-term funding pressure.

$969k available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.

Paid plan

Cash runway history

Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.

Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

Date	Form	Security	Total on issue after	Source
13 July 2026	3G · unquoted	RNV : ORDINARY FULLY PAID	139.2M	Appendix 3G
15 June 2026	3H · cancellation	RNV : ORDINARY FULLY PAID	139.2M	Appendix 3H
30 Apr 2026	3H · cancellation	RNV : ORDINARY FULLY PAID	139.2M	Appendix 3H
30 Mar 2026	3H · cancellation	RNV : ORDINARY FULLY PAID	139.2M	Appendix 3H
24 Mar 2026	2A · quoted issue	RNV : ORDINARY FULLY PAID	139.2M	Appendix 2A

Paid plan

Full issuance history

Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).

Join the waitlist

Capital raises

3 cash raises in the last 24 months · 3 in the last 12 months

$1.4M

Convertible note funding facility / Placement of convertible notes

9 July 2026 ACTIVE

Paid plan

Full raise history

Issue price, discount, brokers, purpose and tranche detail for every raise on record.

Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

24.4%

Total overhang · of current shares

0.0%

In the money · at current price

42.1M

Potential new shares

Nov 2027

Nearest expiry

Paid plan

Per-line options & expiry cliffs

Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.

Join the waitlist

Director dealings

Date	Director	Type	Shares	Options	Value	Source
2 Dec 2025	Julian John Chick	Other	—	3.5M	—	3Y notice
2 Dec 2025	David Rhodes	Other	11.5M	2.0M	—	3Y notice
25 Sept 2025	Reginald Stephen Cooper	Buy	100k	—	—	3Y notice